single-chain urokinase-type plasminogen activator (rscu-PA), we designed chimeric rscu-PA derivatives with intrinsic In order to design plasminogen activators with improved thrombin inhibitory activity that showed a higher clot specifithrombolytic properties, bifunctional proteins with both city than prourokinase itself, probably through an increased plasminogen-activating and anticoagulative activity were affinity to the thrombus , constructed by fusing a thrombin-inhibitory moiety to the 1996). These bifunctional chimeras comprise the kringle and carboxy-terminus of a prourokinase derivative lacking protease domain of human rscu-PA fused via the carboxythe growth-factor domain. The thrombin-inhibitory moiety terminus end to a thrombin inhibitory sequence ( Figure 1 ). itself comprises four elements: linker 1, a motif directed
Introduction
The treatment of occlusive disorders, in particular acute myocardial infarction, has been significantly improved by the introduction of streptokinase, urokinase-type (uPA) and tissuetype (tPA) plasminogen activators (for recent reviews, see Bachmann, in press). Both uPA and tPA convert plasminogen into plasmin by a specific cleavage between Arg560 and Val561. Plasmin then induces clot lysis by proteolytic degradation of fibrin. However, several lines of experimental and clinical evidence indicate that the thrombogenic activity of kringle (pink) was taken from an NMR structure analysis of the aminothrombin must be inhibited by anticoagulative co-medication terminal fragment of prourokinase (Hansen et al., 1994) . Coordinates from during thrombolytic treatment in order to achieve acceptable an X-ray structure analysis were used for the protease domain (yellow) potency rates and to avoid early reocclusion (Schneider, 1991; (Spraggon et al., 1995) . The structure of the thrombin inhibitory domain (purple) has been modelled in an arbitrary conformation using WHATIF. Klement et al., 1992; Yao et al., 1992) . The most common ing the desired amino acid sequences. The modified BamHI/ HindIII fragments were then inserted back into pSJ41 or pSJ95, yielding the respective expression plasmid. All modifications and the flanking regions were verified by DNA sequencing. A detailed description of the plasmid construction was given by Wnendt et al. (1996a) . Recombinant expression, refolding of material from inclusion bodies and purification of the chimeric proteins were performed as described previously (Wnendt et al., 1996b) . Protein concentrations were determined by using the BCA assay (Pierce, Oud Beijerland, The Netherlands). All proteins were analysed by SDS-PAGE (10% polyacrylamide) under reducing conditions.
Preparation of the synthetic peptides
Peptides M23P and M37P were synthesized and purified by NeoSystems (Strasbourg, France). Both preparations were Ͼ95% homogeneous based on HPLC analysis. The correct amino acid sequence was verified by automatic sequence analysis using an ABI sequencer (ABI, Weiterstadt, Germany). 
Determination of specific urokinase and anticoagulative
of the chimeric rscu-PA derivatives or peptides. Gaps are marked by (-) .
activity
The specific urokinase activity was assayed using the chromodirected sequence fused via a four to six residues long linker genic substrate S-2444 (L-pyroglutamyl-L-phenylalanyl-Lto the FRS-binding sequence from hirudin suggests that the lysine-p-nitroanilide; Chromogenix, Antwerp, Belgium) as linker is not interacting with thrombin (DiMaio et al., 1990;  descibed previously (Wnendt et al., 1996b) . Maraganore et al., 1990) . The function of this linker sequence
The anticoagulative activity of the chimeric rscu-PA derivais thought to be merely the proper positioning of the active tives was determined by using a standard thrombin time assay: site directed-sequence and the FRS-binding sequence (Yue human citrate-plasma was diluted 10-fold with veronal buffer et al., 1992). Indeed, based on an X-ray structural analysis of (Boehringer-Mannheim, Mannheim, Germany) and kept at a complex between Hirulog ® and thrombin, the electron density 37°C for at least 5 min. for the linker is very weak, indicating no defined interactions A 200 µl volume of this dilution was mixed with 50 µl of between the pentaglycinyl linker and thrombin (Skrzypczaksolution containing the rscu-PA sample diluted in veronal Jankun et al., 1991) . However, it should be taken into account buffer. The reaction was started by adding 50 µl of solution that glycine has no side chain prone to molecular interactions. containing 0.2 NIH units of human thrombin (Boehringer-A similar model to that for the interaction between Hirulog ® Mannheim) in veronal buffer and the coagulation time was and thrombin was suggested for the binding of thrombin to measured automatically by a coagulometer (Sarstedt, Sarstedt, the human thrombin receptor which contains a cleavage site Germany). Each thrombin time determination was performed for thrombin separated by a linker from an FRS-binding in duplicate. sequence (Vu et al., 1991b) . The chimeric rscu-PA derivative M32 (Figure 2 ) which carries the linker and FRS-binding Determination of K i values for inhibition of thrombinsequence from the human thrombin receptor displayed a mediated cleavage of chromogenic substrates relatively good anticoagulative activity compared with other
The K i values were determined using S-2238 (D-phenylalanylchimeric rscu-PA derivatives containing an artificial spacer L-pipecolyl-L-arginine-p-nitroanilide; Chromogenix) or L-1150 and the FRS-binding sequence from hirudin (Wnendt et al., (benzoyl-L-phenylalanyl-L-valinyl-L-arginine-p-nitroanilide; . This observation led to the assumption that the amino Bachem, Heidelberg, Germany) at concentrations of 20, 30, acid sequence linking the cleavage site and the FRS-binding 40, 60, 80 and 200 µM with 0.04 IU thrombin in a 200 µl sequence of the thrombin receptor may contribute to the assay volume. The chimeric rscu-PA derivatives were tested interaction between thrombin and the chimeric rscu-PA derivaat concentrations between 1.2 and 870 nM. Hirudin (American tive M32. In order to assess the role of linker 2 and to improve further the thrombin-inhibitory activity of the chimeric rscuDiagnostics, Loxo, Dossenheim, Germany) was tested at con-PA derivative M23, we constructed three new chimeras in centrations between 7.5 and 750 pM. The buffer solution which linker 2 and also the FRS-binding sequence were consisted of 90 mM NaCl, 45 mM Tris-HCl, containing 0.02% modified by using sequences from the thrombin receptor and Triton X-100, pH 8. Each determination was performed in hirudin, respectively.
duplicate. The initial rate of the reaction was determined using an SLT microplate reader (405 nm) and evaluated with Materials and methods EasyKin-software (SLT, Crailsheim, Germany). Based on the molar absorption coefficient of p-nitroanilide at 405 nm of Cloning and expression of chimeric rscu-PA derivatives 8800 M -1 cm -1 (Erlanger et al., 1965) , the enzyme velocities All expression vectors were constructed by modifying pSJ41
were calculated and further analysed by the method of and pSJ95 (Steffens et al., 1994) . The BamHI/HindIII fragLineweaver and Burk (Segel, 1975) . Inhibition constants (K i ments of pSJ41 and pSJ95, respectively, were subcloned into values) and inhibition types were determined from DixonpUC18 (Pharmacia, Freiburg, Germany) and modified by insertion of synthetic double-stranded oligonucleotides encodplots of the kinetic data (Segel, 1975) . Molecular structure modelling teins were obtained as at least Ͼ90% homogeneous singlePictures were generated using the program package RASMOL chain preparations with an M r (app) of~43 kDa (Figure v. 2.5 (R.Sayle, Glaxo, Greenford, UK) and WHATIF 4). The specific amidolytic activities of the chimeric u-PA (Vriend, 1990) .
derivatives against the chromogenic substrate S-2444, which mimics the cleavage site of plasminogen recognized by u-PA, Results were found to be in the range 123 000-159 000 Ploug units/ mg (see Table I ). These values were also expected based on Three new chimeric rscu-PA derivatives (M37, M38 and M35) were constructed based on M23 and M32 (Figure 2 ). In the previous work (Wnendt et al., 1996b) . The anticoagulative activity was determined using the case of protein M37 the sequence FLLRNP which corresponds to amino acids Phe43 to Pro48 of the human thrombin receptor thrombin-stimulated coagulation of human plasma as test system. The prolongation of the time necessary to induce (Vu et al., 1991a) was used as linker 2. The entire primary structure of M37 is shown in Figure 3 . In protein M38, linker coagulation (i.e. thrombin time) is a measure for the anticoagulative activity. Figure 5A shows the effect of the three 2 and part of the FRS-binding sequence of hirudin were substituted by the corresponding amino acid sequence from new chimeric rscu-PA derivatives and also their parent molecules M23 and M32 on thrombin time. Clearly there are the human thrombin receptor. Thus, M38 carries a chimeric FRS-binding sequence comprising a fragment from the considerable differences in the degree of anticoagulation between the five proteins: M35 was weaker in its antithrombin receptor and from hirudin. Finally, in protein M35 the synthetic LGGGG linker was substituted by the sequence coagulative activity than any of the other proteins tested and M38 showed an activity which was only slightly stronger than ESHND which is derived from the sequence located between amino acids 49 and 54, N-terminal to the FRS-binding that of its parent M32. Thus, by introducing the sequence ESHND from hirudin as linker 2 in M35 or by constructing a sequence, of hirudin rHV2-Lys47 (ESHNN; Rydel et al., 1990) and native hirudin (QSHND; Dodt et al., 1985) .
composite FRS-binding sequence with elements from hirudin and the thrombin receptor in M38, the anticoagulative activity The three chimeric rscu-PA derivatives were constructed by modification of Escherichia coli expression plasmids pSJ95
could not be increased above the level reached by M23 and M32. However, a surprisingly strong anticoagulative effect and pSJ41, encoding M23 and another chimeric rscu-PA derivative, M12 (Steffens et al., 1994; Wnendt et al., 1996b) , was observed with M37. The concentration of M37 that induces a half-maximal prolongation of thrombin time (i.e. 150 s) is using conventional cloning techniques. The recombinant pro-phenylalanine (Maraganore et al., 1990) . Therefore, a D-Phe residue was also used as amino-terminal amino acid for the synthesis of the peptides M23P and M37P (Figure 2 ). Both peptides were tested with respect to their effect on thrombinstimulated plasma coagulation. M37P showed a stronger anticoagulative activity than M23P ( Figure 5B) ; however, the difference between the two peptides was not so dramatic as observed between the corresponding proteins, M23 and M37.
Comparing the molar concentrations of the corresponding peptides and proteins necessary to achieve a half-maximal for the rscu-PA derivative M37 (0.9 µg/ml, corresponding to 21 nM). In the case of M23 and M23P the bias was towards the peptide M23P since it induced about a twofold stronger Table II domain but is also due to a very good 'presentation' of this
inhibitory domain by the larger rscu-PA moiety. 
Discussion
The present study was carried out in order to evaluate whether about 10-fold lower than that necessary for M23 ( Figure 5A ). These data suggest that the amino acid sequence between the specific 'bridging' sequences taken from hirudin or the human thrombin receptor may enhance the thrombin-inhibitory cleavage site and the FRS-binding sequence of the human thrombin receptor used as linker 2 may contribute substantially activity of the chimeric rscu-PA derivative M23 (Wnendt et al., 1996b) . While no increase in inhibitory activity was observed to the thrombin-inhibitory activity of the chimeric rscu-PA derivative M37.
when the sequence between the active site directed sequence and the FRS-binding sequence was substituted by a pentaThe strong inhibitory activity of M37 was further confirmed in a direct assay of thrombin inhibition in which a K i value meric sequence derived from hirudin, a very significant and pronounced enhancement was conferred by introduction of the of 2.0 ϩ 0.5 nM for thrombin-mediated cleavage of the chromogenic substrate L-1150 was determined. This value is sequence FLLRNP as linker 2 in rscu-PA derivative M37. In contrast to M23, the new chimera is able to inhibit approximately two orders of magnitude lower than the K i values found for the parent chimeras M23 and M32 and only competitively the thrombin-mediated cleavage of S-2238, which has a relatively high affinity to thrombin. However, the 50 times higher than the inhibition constant of hirudin (Table  II) . Based on Dixon plot analysis it was found that M37 enhancement of thrombin-inhibitory activity was less dramatic when the sequence from the human thrombin receptor was inhibits thrombin in a competitive fashion (not shown). The significant improvement in thrombin inhibitory activity was introduced in a chimeric bifunctional peptide with thrombin inhibitory activity. This may be explained by the introduction also demonstrated by the fact that M37, in contrast to M23, is able to inhibit the thrombin-mediated cleavage of S-2238 of the NH 2 -terminal phenylalanine with D-configuration, which confers a very high thrombin inhibitory activity to bifunctional (Table II) . S-2238 is another thrombin-specific chromogenic substrate has a much higher affinity for thrombin than L-1150, peptides such as M23P or M37P (Maraganore et al., 1990) and, therefore, may superimpose the effect of the substitution since the K m value of thrombin for S-2238 is 7 µM compared with 160 µM for L-1150 (supplier's datasheet; Svendsen et al., of linker 2. Also, it may be conceivable that the protease domain supports a proper 'presentation' of the thrombin 1972). Consequently, the K i values of M37 and of hirudin obtained with S-2238 are higher; indicating that higher conceninhibitory moiety. The enhancing effect of the introduction of the sequence trations of the respective competitive inhibitor are necessary to displace the substrate from the active centre of thrombin.
from the human thrombin receptor may be explained by a direct interaction of linker 2 with thrombin, which is in contrast The inhibition of thrombin-mediated cleavage of S-2238 by M37 indicates that this chimeric rscu-PA derivitate has a to current models of interaction between thrombin and its receptor (Vu et al., 1991b) . Based on the X-ray structure of substantially increased affinity to thrombin compared with its parent compound M23.
thrombin, it is known that there are two glutamic acid residues (Glu39 and Glu192) positioned at the exit of the substrate In order to investigate further the unforeseen high thrombininhibitory activity of M37, two synthetic peptides were binding pocket in the vicinity of the fibrinogen-recognition site (Stubbs and Bode, 1995; Figure 6 ). The basic arginine designed which carry the active-site-directed sequence, linker 2 and the FRS-binding sequence of either M23 or M37. In the residue (Arg378) present in linker 2 of M37 may interact with one of these acidic residues and therefore facilitate the case of the Hirulogs ® it was found that a phenylalanine residue with D-configuration at the amino terminus is associated with interaction of the inhibitory domain with thrombin. In addition, Glu39 and Glu192 may also account for the decreased thrombin a substantially higher thrombin inhibitory activity than L-goal. Using the thrombin time assay it was demonstrated previously that the anticoagulative activity of M23 is~20-fold lower than that of hirudin (Lijnen et al., 1995) . However, a half-maximal prolongation of thrombin-time is achieved at a concentration of~21 nM for M37 (see Results) and~5 nM for hirudin (data not shown), indicating that the new chimeric rscu-PA derivative is only about fourfold weaker than hirudin. Since the plasminogen activating activity of M37 is very similar to that of Saruplase (about 150 000 Ploug units/mg) or M23 (see Table II ), it may be assumed that the therapeutic dose for fibrinolytic therapy will be similar to that of Saruplase, which is about 1 mg/kg (Diefenbach et al., 1988) . Recent data from clinical trials with hirudin as an adjunct during fibrinolytic therapy indicate that the initial dosis administered together with the plasminogen activator will be 0.1-0.2 mg/kg or even lower (Zeymer and Neuhaus, 1995) . Therefore, when M37 is applied at a dose of 1 mg/kg, the anticoagulative activity may be sufficient to substitute the initial co-medication with heparin
